Jupiter Neurosciences Expands Nugevia™ Addressable Market with GLP-1 Users

Jupiter Neurosciences is expanding its Nugevia™ addressable market by focusing on GLP-1 users. The company sees an opportunity to serve a growing population seeking science-backed, pharmaceutical-grade solutions that extend beyond weight loss. Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss. Jupiter believes this initiative reinforces its dual-engine strategy of combining a clinical-stage pharmaceutical pipeline with a direct-to-consumer longevity business.